CORK, M.; THA?I, D.; EICHENFIELD, L.; ARKWRIGHT, P.; CHEN, Z.; KAMAL, M.; O’MALLEY, J.; BANSAL, A. Dupilumab Provides Acceptable Long-Term Safety and Efficacy in Children Aged ≥ 6 to < 12 Years with Uncontrolled, Severe Atopic Dermatitis: Results From Patients Who Participated in an Open-Label Phase 2a Study and then in a Subsequent Phase 3 Open-Label Extension Study. SKIN The Journal of Cutaneous Medicine, [S. l.], v. 4, n. 6, p. s104, 2020. DOI: 10.25251/skin.4.supp.104. Disponível em: https://jofskin.org/index.php/skin/article/view/1100. Acesso em: 3 jul. 2024.